New TYK2 Inhibitors for Psoriasis Achieve High Clearance Rates in Randomized Trials

(MedPage Today) -- DENVER -- Two drug candidates to expand oral therapy options for psoriasis had similar and consistent performances in separate phase III clinical trials reported here. The allosteric TYK2 inhibitor zasocitinib achieved at...
Source
MedPage Today
Opens original article in a new tab



